CRF Connect Logo

Coronary

Clinical Indications and Science Learning Series

ACS and Primary PCI

Advertisement

Coronary >
ACS and Primary PCI

Episodes

Coronary Keynote Lecture: My Personal Guide to Prevention and Management of Primary PCI Complications
Coronary Keynote Lecture: My Personal Guide to Prevention and Management of Primary PCI Complications
10 min.
Drug-Coated Balloon for Acute Coronary Syndromes: A Multicenter Randomized Non-inferiority Trial (DCB-ACS Trial)
Drug-Coated Balloon for Acute Coronary Syndromes: A Multicenter Randomized Non-inferiority Trial (DCB-ACS Trial)
15 min.
Imaging and Physiology in STEMI: Which Technology and When
Imaging and Physiology in STEMI: Which Technology and When
15 min.
Managing STEMI No Reflow
Managing STEMI No Reflow
14 min.
Giant Thrombus: Management and Options
Giant Thrombus: Management and Options
13 min.
Pharmacology for STEMI PCI: Which Therapies Before, Options During the Case, and Management Post
Pharmacology for STEMI PCI: Which Therapies Before, Options During the Case, and Management Post
13 min.
STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors
STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors
16 min.
Thrombus Aspiration for STEMI Patients
Thrombus Aspiration for STEMI Patients
13 min.
Unloading of the Left Ventricle
Unloading of the Left Ventricle
5 min.
Addressing Microvascular Obstruction with SSO2
Addressing Microvascular Obstruction with SSO2
5 min.
Staged Non-Culprit Lesion PCI Is Safer and Better for the Patient!
Staged Non-Culprit Lesion PCI Is Safer and Better for the Patient!
10 min.
Complete Revascularization in Patients With STEMI and MVD: CV Outcomes, Quality of Life, and Future Directions
Complete Revascularization in Patients With STEMI and MVD: CV Outcomes, Quality of Life, and Future Directions
7 min.
Immediate Non-Culprit Lesion PCI Is the Way to Go!
Immediate Non-Culprit Lesion PCI Is the Way to Go!
6 min.
STEMI State-of-the-Art: An Angiography-Guided Strategy!
STEMI State-of-the-Art: An Angiography-Guided Strategy!
3 min.
STEMI State-of-the-Art: A Physiology-Guided Strategy!
STEMI State-of-the-Art: A Physiology-Guided Strategy!
5 min.
STEMI State-of-the-Art: An Imaging-Guided Strategy!
STEMI State-of-the-Art: An Imaging-Guided Strategy!
8 min.
Reperfusion of the Infarct Related Artery With Timely Primary PCI
Reperfusion of the Infarct Related Artery With Timely Primary PCI
5 min.
Antithrombotic Therapy in ACS/PCI: Case Resolution and Long-term Therapy
Antithrombotic Therapy in ACS/PCI: Case Resolution and Long-term Therapy
8 min.
The Guidelines Need Updating: 3-6 Months of DAPT Is Sufficient
The Guidelines Need Updating: 3-6 Months of DAPT Is Sufficient
7 min.
Longer Term DAPT Is What The Guidelines and Data Support
Longer Term DAPT Is What The Guidelines and Data Support
7 min.
Antithrombotic Therapy in ACS/PCI: Case Continuation and In Hospital Management
Antithrombotic Therapy in ACS/PCI: Case Continuation and In Hospital Management
4 min.
I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors
I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors
10 min.
Cangrelor Reduces Procedural Complications and Should Be the Default Strategy
Cangrelor Reduces Procedural Complications and Should Be the Default Strategy
9 min.
Unfractionated Heparin Still Works for Primary PCI!
Unfractionated Heparin Still Works for Primary PCI!
11 min.
Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI
Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI
8 min.
Case Presentation: Antithrombotic Therapy in ACS/PCI
Case Presentation: Antithrombotic Therapy in ACS/PCI
3 min.
Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial
Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial
24 min.
Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction: The Randomized PICSO-AMI-I Trial
Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction: The Randomized PICSO-AMI-I Trial
22 min.
How I Use Intravascular Imaging to Guide PCI in Acute Coronary Syndromes
How I Use Intravascular Imaging to Guide PCI in Acute Coronary Syndromes
19 min.
Con: Favorable Data Is Lacking on MCS in AMI Cardiogenic Shock (Randomized Data Are Needed)
Con: Favorable Data Is Lacking on MCS in AMI Cardiogenic Shock (Randomized Data Are Needed)
17 min.
Pro: Most Patients With AMI Cardiogenic Shock Should Get MCS (Randomization Is Unethical)
Pro: Most Patients With AMI Cardiogenic Shock Should Get MCS (Randomization Is Unethical)
6 min.
Con: Percutaneous LVADs are not the First Line MCS device of choice for Acute MI & Cardiogenic Shock
Con: Percutaneous LVADs are not the First Line MCS device of choice for Acute MI & Cardiogenic Shock
15 min.
Pro: Percutaneous LVADs are the First Line MCS device of choice for Acute MI & Cardiogenic Shock
Pro: Percutaneous LVADs are the First Line MCS device of choice for Acute MI & Cardiogenic Shock
6 min.
Coronary Keynote Lecture: Novel Approaches to STEMI Care
Coronary Keynote Lecture: Novel Approaches to STEMI Care
10 min.
Coronary Keynote Lecture: New Concepts in Primary PCI: What Should I Be Doing Differently
Coronary Keynote Lecture: New Concepts in Primary PCI: What Should I Be Doing Differently
11 min.
Case Presentation: Young MI with Multivessel Disease
Case Presentation: Young MI with Multivessel Disease
10 min.
Refractory Cardiogenic Shock With Severe LV Dysfunction and a Mechanical Complication of Inferior Wall MI
Refractory Cardiogenic Shock With Severe LV Dysfunction and a Mechanical Complication of Inferior Wall MI
13 min.
Unloading in AMI:  Changing the Paradigm from DTB to DTU
Unloading in AMI: Changing the Paradigm from DTB to DTU
9 min.
How Important Is Complete Revascularization?
How Important Is Complete Revascularization?
7 min.
For Most Patients, Only Spontaneous MI Is Relevant
For Most Patients, Only Spontaneous MI Is Relevant
6 min.
Management of High Thrombus Burden in STEMI
Management of High Thrombus Burden in STEMI
8 min.
STEMI and MVD Update on the Evidence: Rationale for COMPLETE 2
STEMI and MVD Update on the Evidence: Rationale for COMPLETE 2
8 min.
STEMI with Multivessel Disease: Managing the Non-Culprit Vesel
STEMI with Multivessel Disease: Managing the Non-Culprit Vesel
3 min.
ACS with a Large Thrombus Burden: Thrombectomy Revisited ? Guidelines Recommendations
ACS with a Large Thrombus Burden: Thrombectomy Revisited ? Guidelines Recommendations
3 min.
Thrombectomy Case Presentation
Thrombectomy Case Presentation
5 min.
Case Presentation:  Managing the Non-Culprit Vessel in STEMI with Multivessel Disease:
Case Presentation: Managing the Non-Culprit Vessel in STEMI with Multivessel Disease:
4 min.
TCT 688: An Unfortuante Trifecta: A case of  acute myocardial infarction with cardiogenic shock, pericardial tamponade, and worsening hypoxia with right to left shunt after percutaneous LVAD placement.
TCT 688: An Unfortuante Trifecta: A case of  acute myocardial infarction with cardiogenic shock, pericardial tamponade, and worsening hypoxia with right to left shunt after percutaneous LVAD placement.
6 min.
TCT 640: POST MYOCARDIAL INFARCTION VENTRICULAR SEPTAL RUPTURE WITH HEART FAILURE AND CARDIOGENIC SHOCK : CHALLENGES AND DEVICE CLOSURE
TCT 640: POST MYOCARDIAL INFARCTION VENTRICULAR SEPTAL RUPTURE WITH HEART FAILURE AND CARDIOGENIC SHOCK : CHALLENGES AND DEVICE CLOSURE
6 min.
TCT 659: Acute Mitral Regurgitation With Unilateral Left-Sided Pulmonary Edema: A Complication of STEMI Treated Successfully With A Mitra-Clip Procedure
TCT 659: Acute Mitral Regurgitation With Unilateral Left-Sided Pulmonary Edema: A Complication of STEMI Treated Successfully With A Mitra-Clip Procedure
6 min.
Periprocedural MI Matters to All Patients!
Periprocedural MI Matters to All Patients!
4 min.
Should We Be Stenting All Patients Presenting With STEMI? Pros and Cons
Should We Be Stenting All Patients Presenting With STEMI? Pros and Cons
8 min.
New and Emerging Pharmacology for ACS: Lipid Modulation and Anti-Inflammatory Agents
New and Emerging Pharmacology for ACS: Lipid Modulation and Anti-Inflammatory Agents
8 min.
New and Emerging Pharmacology for ACS: Factor XI Inhibition
New and Emerging Pharmacology for ACS: Factor XI Inhibition
6 min.
State-of-the Art: Top 10 Lessons We Have Learned In ACS Management
State-of-the Art: Top 10 Lessons We Have Learned In ACS Management
12 min.
Short DAPT or De-Escalation After ACS
Short DAPT or De-Escalation After ACS
7 min.
P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?
P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?
7 min.
Hemodynamic Support for High-Risk PCI in ACS
Hemodynamic Support for High-Risk PCI in ACS
8 min.
PCI in STEMI - Never Treat the Non-Culprit in the Same Setting
PCI in STEMI - Never Treat the Non-Culprit in the Same Setting
3 min.
Management of No-Reflow in ACS
Management of No-Reflow in ACS
2 min.
PCI in STEMI -  Complete Revascularization As Long As You Can Manage the Contrast/Hemodynamics
PCI in STEMI - Complete Revascularization As Long As You Can Manage the Contrast/Hemodynamics
4 min.